ArticlePloS one2023
Linear programming based computational technique for leukemia classification using gene expression profile.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- LncRNA NEAT1 restrains the malignant biological characteristics of acute myeloid leukemia via regulating CTCF/CXCR2 axis.Clinical and experimental medicine · 2025Article
- P-Glycoprotein as a Therapeutic Target in Hematological Malignancies: A Challenge to Overcome.International journal of molecular sciences · 2025Review
- An efficient leukemia prediction method using machine learning and deep learning with selected features.PloS one · 2025Article
- Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?Cancers · 2024Review
- Gene Expression-Based Cancer Classification for Handling the Class Imbalance Problem and Curse of Dimensionality.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a serious public health concern worldwide and is the leading cause of death. Blood cancer is one of the most dangerous types of cancer. Leukemia is a type of cancer that affects the blood cell and bone marrow. Acute leukemia is a chronic condition that is fatal if left untreated. A timely, reliable, and accurate diagnosis of leukemia at an early stage is critical to treating and preserving patients' lives. There are four types of leukemia, namely acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic in extracting, and chronic myelogenous leukemia. Recognizing these cancerous development cells is often done via manual analysis of microscopic images. This requires an extraordinarily skilled pathologist. Leukemia symptoms might include lethargy, a lack of energy, a pale complexion, recurrent infections, and easy bleeding or bruising. One of the challenges in this area is identifying subtypes of leukemia for specialized treatment. This Study is carried out to increase the precision of diagnosis to assist in the development of personalized plans for treatment, and improve general leukemia-related healthcare practises. In this research, we used leukemia gene expression data from Curated Microarray Database (CuMiDa). Microarrays are ideal for studying cancer, however, categorizing the expression pattern of microarray information can be challenging. This proposed study uses feature selection methods and machine learning techniques to predict and classify subtypes of leukemia in gene expression data CuMiDa (GSE9476). This research work utilized linear programming (LP) as a machine-learning technique for classification. Linear programming model classifies and predicts the subtypes of leukemia Bone_Marrow_CD34, Bone Marrow, AML, PB, and PBSC CD34. Before using the LP model, we selected 25 features from the given dataset of 22283 features. These 25 significant features were the most distinguishing for classification. The classification accuracy of this work is 98.44%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.